Advances toward improved understanding and treatment of uncommon ovarian cancer types and subtypes


Book Description

Ovarian cancer is an umbrella term for a collection of distinct disease entities (histotypes). Until now, the majority of research has focussed on the most common histotype, high-grade serous ovarian carcinoma (HGSOC), which accounts for 70% of cases. The less common histotypes – including endometrioid, clear cell, mucinous, low-grade serous, carcinosarcoma, and non-epithelial histotypes – have received far less research attention. Accordingly, while major advances in our understanding of HGSOC have led to molecularly-directed therapies that improve patient outcomes, progress in less common histotypes has lagged behind. Notably, many of the uncommon histotypes demonstrate resistance to conventional chemotherapy regimens, and their inherent biological differences suggest most are unlikely to respond to emerging molecular therapeutics designed to target the biology of common ovarian cancer types.




Ovarian Cancers


Book Description

In an era of promising advances in cancer research, there are considerable and even alarming gaps in the fundamental knowledge and understanding of ovarian cancer. Researchers now know that ovarian cancer is not a single disease-several distinct subtypes exist with different origins, risk factors, genetic mutations, biological behaviors, and prognoses. However, persistent questions have impeded progress toward improving the prevention, early detection, treatment, and management of ovarian cancers. Failure to significantly improve morbidity and mortality during the past several decades is likely due to several factors, including the lack of research being performed by specific disease subtype, lack of definitive knowledge of the cell of origin and disease progression, and incomplete understanding of genetic and non-genetic risk factors. Ovarian Cancers examines the state of the science in ovarian cancer research, identifies key gaps in the evidence base and the challenges to addressing those gaps, considers opportunities for advancing ovarian cancer research, and examines avenues for translation and dissemination of new findings and communication of new information to patients and others. This study makes recommendations for public- and private-sector efforts that could facilitate progress in reducing the incidence of morbidity and mortality from ovarian cancers.




Blaustein's Pathology of the Female Genital Tract


Book Description

New edition includes more than 350 new illustrations and 22 revised chapters Written by internationally recognized experts Each entry is structured the same way, from general to more specific information, which allows the reader to quickly access key information in every chapter Since the publication of the 1/e in 1977, Blaustein's Pathology of the Female Genital Tract has consolidated its position as the leading textbook of gynecological pathology. an essential reference for all pathologists and residents, this thoroughly updated Sixth Edition includes more than 1500 illustrations in color, i




Ovarian Cancer


Book Description

Ovarian cancer management is a rapidly changing field with new treatment agents available as a result of a greater understanding of the pathogenesis of this disease. In addition, both surgical and chemotherapeutic treatment strategies are evolving to maximise response in this disease. This book brings together leading specialists from around the world to discuss and outline a variety of new concepts in ovarian cancer, ranging from molecular biology and genetics through screening to both surgical and chemotherapeutic management.




Ovarian Cancer Biomarkers


Book Description

This book comprehensively summarizes the biology, etiology, and pathology of ovarian cancer and explores the role of deep molecular and cellular profiling in the advancement of precision medicine. The initial chapter discusses our current understanding of the origin, development, progression and tumorigenesis of ovarian cancer. In turn, the book highlights the development of resistance, disease occurrence, and poor prognosis that are the hallmarks of ovarian cancer. The book then reviews the role of deep molecular and cellular profiling to overcome challenges that are associated with the treatment of ovarian cancer. It explores the use of genome-wide association analysis to identify genetic variants for the evaluation of ovarian carcinoma risk and prognostic prediction. Lastly, it highlights various diagnostic and prognostic ovarian cancer biomarkers for the development of molecular-targeted therapy.




Surgery for Ovarian Cancer


Book Description

Updated and expanded, the third edition of Surgery for Ovarian Cancer focuses on essential techniques for the effective management of ovarian cancer. It reflects the most contemporary science and surgical applications for the management of patients with ovarian cancer and related peritoneal surface malignancies. This new edition takes a step-by-step approach and includes new intraoperative photographs and videos illustrating surgical procedures. It is principally devoted to the technical aspects of cytoreductive surgery, with chapters divided according to anatomic region. The chapters cover relevant anatomical considerations, surgical challenges specific to each region, and operative approaches and techniques favored by the authors. The list of contributing authors has been expanded from the previous edition and includes international and world-renowned experts from the fields of gynecologic oncology and surgical oncology. The topics of minimally invasive surgery, secondary cytoreduction, palliative surgery, and postoperative care are also covered in detail. New to the third edition are chapters on preoperative risk stratification, regional therapeutics and peritonectomy procedures, and quality assurance relating to ovarian cancer surgery. This comprehensive text is essential reading for all practitioners working with patients with ovarian cancers.




A National Cancer Clinical Trials System for the 21st Century


Book Description

The National Cancer Institute's (NCI) Clinical Trials Cooperative Group Program has played a key role in developing new and improved cancer therapies. However, the program is falling short of its potential, and the IOM recommends changes that aim to transform the Cooperative Group Program into a dynamic system that efficiently responds to emerging scientific knowledge; involves broad cooperation of stakeholders; and leverages evolving technologies to provide high-quality, practice-changing research.




Diagnosis and Management of Ovarian Disorders


Book Description

This updated second edition of Diagnosis and Management of Ovarian Disorders provides thorough, yet succinct insight into the ever-changing realm of ovarian disorders. It presents a novel multidisciplinary approach to the subject as described by clinicians, surgeons, pathologists, basic scientists and related medical researchers. Topics covered include reproductive technology, early diagnosis of ovarian cancer, and management of menopause among others. The breadth of information provided by this book will appeal to clinicians and researchers involved in the study and treatment of ovarian disorders.KEY FEATURES* Includes updated information on early diagnosis of ovarian cancer* Reviews new diagnostic techniques for ovarian disorders* Discusses latest information on reproductive technology* Presents translational treatment linking laboratory research with clinical medicine




Plasma in Cancer Treatment


Book Description

In the last decade, research on cold atmospheric plasma (CAP) has significantly advanced our understanding of the effect of CAP on cancer cells and their potential for cancer treatment. This effect is due to the reactive oxygen and nitrogen species (RONS) created by plasma. This has been demonstrated for different cancer cell lines and the first clinical trials showed promising results. In addition, plasma could be combined with other treatments-such as immunotherapy-to boost its anticancer activity. The addition of new research tools to study the response of cancer cells to CAP-such as 3D in vitro, in ovo, and in vivo models and in silico approaches-as well as the use of -OMICS technologies could aid in unravelling the underlying mechanisms of CAP in cancer treatment. In order to progress towards widespread clinical application of CAP, an integrated study of the multidimensional effect of CAP in cancer treatment is essential. In this book, reviews and original research papers are published that provide new insights into the mechanisms of cold atmospheric plasma in cancer treatment, based on in vitro and in vivo experiments, clinical studies, as well as computer modeling.




The Genetics of Cancer


Book Description

It has been recognized for almost 200 years that certain families seem to inherit cancer. It is only in the past decade, however, that molecular genetics and epidemiology have combined to define the role of inheritance in cancer more clearly, and to identify some of the genes involved. The causative genes can be tracked through cancer-prone families via genetic linkage and positional cloning. Several of the genes discovered have subsequently been proved to play critical roles in normal growth and development. There are also implications for the families themselves in terms of genetic testing with its attendant dilemmas, if it is not clear that useful action will result. The chapters in The Genetics of Cancer illustrate what has already been achieved and take a critical look at the future directions of this research and its potential clinical applications.




Recent Books